[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kunming Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,62,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100635841","phase-2-a-multicentre-randomised-double-blind-positive-control-clinical-trial-evaluating-dihydroartemisinin-tablets-for-the-treatment-of-discoid-lupus-erythematosus-100635841",false,"NCT07557927","A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus","Inclusion Criteria:\n\n1. Participants are able to understand the purpose and risks of the study and voluntarily sign an informed consent form;\n2. Aged between 18 and 65 years (inclusive);\n3. Body weight ≥ 45 kg;\n4. Diagnosed with discoid lupus erythematosus (DLE) at the screening visit (refer to the '2021 Guidelines for the Diagnosis, Treatment and Long-term Management of Cutaneous Lupus Erythematosus'); new patients must undergo a skin biopsy and provide a pathology report, whilst existing patients must provide a biopsy pathology report dated within the last 5 years;\n5. At the time of screening, the Cutaneous Lupus Erythematosus Area and Severity Index (CLASI-A) must be ≥4.\n\nExclusion Criteria:\n\n1. Patients with systemic lupus erythematosus (SLE) or those at high risk of developing SLE;\n2. Drug-induced lupus;\n3. Patients with a history of resistance to antimalarial treatment;\n4. At screening, aspartate transaminase (AST) or alanine transaminase (ALT) or gamma-glutamyltransferase (GGT) levels exceeding twice the upper limit of normal (ULN); or alkaline phosphatase (ALP) or total bilirubin levels exceeding 1.5 times the upper limit of normal (ULN); or serum creatinine (Cr) or urea (UREA) levels exceeding 1.5 times the upper limit of normal (ULN);\n5. Patients diagnosed with anaemia within 3 months prior to randomisation, or patients with haemoglobin levels below 110 g\u002FL at screening;\n6. Patients who have used any antimalarial drug (hydroxychloroquine sulphate, chloroquine phosphate or chloroquine) within 4 weeks prior to randomisation;\n7. Patients who have used topical corticosteroids (e.g. mometasone furoate cream or others) or topical calcineurin inhibitors (e.g. tacrolimus ointment or others) within 2 weeks prior to randomisation;\n8. Patients treated with biologics (e.g. adalimumab, secukinumab or others) within 12 weeks prior to randomisation;\n9. Patients treated with immunomodulators (e.g. thalidomide, lenalidomide or others) within 4 weeks prior to randomisation;\n10. Patients who have received live vaccines (e.g. measles vaccine, varicella vaccine or others) within 4 weeks prior to randomisation;\n11. Patients who have used traditional Chinese medicinal preparations with lupus-modulating effects within 4 weeks prior to randomisation, such as Tripterygium preparations (e.g. Tripterygium glycosides), Paeonia lactiflora total glycosides capsules, Zhengqing Fengtongning, or Euphorbia root tablets;\n12. History of malignant tumours within the 5 years prior to screening;\n13. History of acute myocardial infarction, unstable angina, or severe arrhythmias (multifocal frequent premature ventricular contractions, ventricular tachycardia, ventricular fibrillation) within the 6 months prior to screening, or New York Heart Association (NYHA) Class III-IV;\n14. Conditions not effectively controlled at the time of screening or markedly unstable diseases (such as acute pneumonia, pulmonary arterial hypertension, diabetic ketoacidosis, acute pancreatitis, etc.), which, in the investigator's judgement, may confound the study results or expose the participant to undue risk;\n15. Patients with a history of major organ transplantation (e.g., heart, lung, kidney, liver) or haematopoietic stem cell and\u002For bone marrow transplantation within the 5 years prior to screening;\n16. A history of chronic, recurrent (three or more episodes of the same type of infection within 52 weeks) or recent severe infections (e.g. pneumonia, sepsis), including viral infections (particularly varicella and herpes zoster), or requiring anti-infective treatment during the screening period;\n17. Patients who have undergone any major surgery within 6 weeks prior to randomisation, such as abdominal, thoracic or joint replacement surgery, or who are scheduled to undergo major surgery during the study (including follow-up);\n18. Patients for whom the investigator, based on an ophthalmological examination prior to randomisation, considers the findings to be clinically significant and unsuitable for participation in this clinical trial, or who have diseases associated with retinal pathology;\n19. Pregnant or breastfeeding women, or women of childbearing potential who do not agree to use effective contraception during the clinical trial;\n20. Patients with known hypersensitivity to artemisinin-based drugs, hydroxychloroquine or excipients (lactose, microcrystalline cellulose, sodium carboxymethyl starch, sodium dodecyl sulphate, polyvinylpyrrolidone, magnesium stearate);\n21. Any other circumstances, as determined by the investigator, that may interfere with the assessment of efficacy.\n22. Individuals who abuse drugs or alcohol;\n23. Participants who have taken part in any clinical trial within the three months prior to screening (excluding those who underwent safety checks only and did not receive any substantive medication or therapeutic.","ALL","18 Years","65 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid lupus erythematosus (DLE).",[26],"Discoid Lupus Erythematosus","NOT_YET_RECRUITING","2026-04-22",{"date":30,"type":31},"2026-04-30","ACTUAL",{"date":30,"type":20},{"date":34,"type":20},"2028-09-30",{"name":36,"class":37},"Kunming Pharmaceuticals, Inc.","INDUSTRY",10,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100625400","phase-1-a-phase-i-clinical-study-to-evaluate-the-safety-tolerability-and-pharmacokinetic-profile-of-gastrodin-injection-in-healthy-chinese-subjects-100625400","NCT07422142","A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects","Inclusion Criteria:\n\n1. Subjects must have a full understanding of the trial's purpose, nature, procedures, and potential adverse reactions, voluntarily consent to participate as subjects, sign the informed consent form prior to the initiation of any research procedures, be capable of effective communication with investigators, and understand and comply with all requirements of the study.\n2. Healthy male or female subjects aged 18 to 65 years (inclusive of boundary values), with a male-to-female ratio of 1:1.\n3. Male subjects with a body weight ≥ 50.0 kg and female subjects with a body weight ≥ 45.0 kg. body mass index (BMI) ranging from 19.0 to 26.0 kg\u002Fm² (inclusive of boundary values) .\n4. Subjects must have no fertility plans during the trial period and within 3 months after the final administration, voluntarily adopt effective contraceptive measures, and have no plans to donate sperm or eggs.\n\nExclusion Criteria:\n\n1. Subjects who developed acute diseases within 2 weeks prior to screening, such as acute gastroenteritis, acute upper respiratory tract infection, acute appendicitis, etc.\n2. Subjects with a history of any clinically severe diseases or conditions that the investigator deems may interfere with the evaluation of the safety or pharmacokinetic properties of the investigational drug, including but not limited to diseases of the circulatory, respiratory, endocrine, nervous, digestive, urinary systems, as well as hematological, immunological, psychiatric, and metabolic diseases.\n3. Subjects who underwent major surgery within 6 months prior to screening, or plan to undergo surgery during the study period or within 1 month after the trial completion.\n4. Subjects with an allergic diathesis (known hypersensitivity to two or more drugs) or known hypersensitivity to Gastrodin Injection and its related excipients.\n5. Subjects who donated blood within 3 months prior to screening, lost a total of ≥ 400 mL of blood due to blood donation or other causes (excluding normal menstrual blood loss in females) within 6 months prior to screening, or have a history of unexplained abnormal bleeding .\n6. Subjects who cannot tolerate venipuncture, indwelling needles or have a history of trypanophobia or hematophobia.\n7. Subjects with special dietary requirements who are unable to comply with the unified diet.\n8. Subjects who participated in other clinical trials and received investigational drugs or devices within 3 months prior to screening (Note: The end time is defined as the date of the last visit for trial discharge).\n9. Subjects who received live attenuated vaccine within 2 weeks prior to screening or require live attenuated vaccine during the trial period.\n10. Subjects who used any medications (including prescription drugs, nonprescription drugs, and Chinese herbal medicines) within 2 weeks prior to screening; Subjects who have consumed strong tea, beverages containing caffeine or alcohol or pomelos, grapefruits and their juices which affect drug metabolism, within 48 hours prior to screening.\n11. Subjects with an average daily cigarette consumption of more than 5 cigarettes within 3 months prior to screening, or those who cannot discontinue the use of any tobacco products during the trial period.\n12. Subjects with a history of drug abuse (including non-medical use of various narcotic drugs and psychotropic substances) in the past year, or those with positive results in drug abuse screening (including morphine, methamphetamine, ketamine, ecstasy, tetrahydrocannabinolic acid).\n13. Subjects with alcoholism, or those who consumed alcohol frequently within 6 months prior to screening (specifically: \\>14 units per week. 1 unit = 360 mL of beer, 150 mL of wine, or 45 mL of baijiu), or those with a positive alcohol breath test result at screening, or those who cannot abstain from alcohol during the trial period.\n14. Subjects with clinically significant abnormalities in vital signs assessment, physical examination, chest X-ray (posteroanterior view), clinical laboratory tests (complete blood count, urinalysis, blood biochemistry, coagulation function), and 12-lead electrocardiogram.\n15. Subjects with positive results in any item of infectious disease screening during the screening period (including hepatitis B surface antigen, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus antibody, syphilis antibody).\n16. Other subjects deemed unsuitable for participation by the investigator.\n\n    Female subjects should also be excluded if they meet the following conditions in addition to the above requirements:\n17. Those who have had unprotected sexual intercourse with their partners within 14 days before screening.\n18. Women with positive pregnancy test results or those who are lactating.\n19. Women whose menstrual period is expected to occur during the drug administration and safety observation period.",true,{"count":47,"type":20},54,[49],"PHASE1","This is a single-center, double-blind study to evaluate the safety, tolerability, pharmacokinetics of Gastrodin Injection in healthy Subjects",[52],"Delirium","2026-02-12",{"date":55,"type":31},"2026-02-19",{"date":57,"type":20},"2026-03-01",{"date":59,"type":20},"2026-09-30",{"name":36,"class":37},1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100614430","phase-2-efficacy-and-safety-of-the-kpcxm18-injection-in-patients-with-acute-ischemic-stroke-100614430","NCT07279493","Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke","A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase Ⅱb Clinical Trial to Evaluate the Efficacy and Safety of the KPCXM18 Injection at Different Doses in The Treatment of Acute Ischemic Stroke","KPCXM18","Inclusion Criteria:\n\n* 1\\. Age 18 to 80 years old (including 18 years old and 80 years old, based on the date of signing the informed consent form), male or female;\n* 2.Diagnosed with acute ischemic stroke according to the \" Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023 \";\n* 3.During the screening process, it is required that the ischemic stroke should occur within 12 hours after the onset, and it is expected that the investigational drug can be started within 12 hours after the onset; note: The onset time is calculated from the time when the ischemic stroke symptoms appear, If the onset occurs during sleep, the time of onset should be considered as the last time the patient was observed to be normal;\n* 4.Before intravenous thrombolysis, 6 points ≤ NIHSS score ≤ 24 points, and the sum of upper limb and lower limb score ≥2 points;\n* 5.The patients who first attacked, or the patients who had a good prognosis after the last attacked , (mRS score was ≤1 before the onset of the disease );\n* 6.The subject has received or plans to receive standard intravenous thrombolysis treatment after this onset;\n* 7.The subject can understand and follow the research process and voluntarily signs the research informed consent form (the informed consent form is signed by the subject or the legal representative).\n\nExclusion Criteria:\n\n* 1\\. Patients with intracranial hemorrhagic diseases confirmed by Imaging: hemorrhagic stroke, epidural hematoma, intracranial hematoma, subarachnoid hemorrhage, ventricular hemorrhage, Traumatic cerebral hemorrhage, etc;\n* 2\\. Patients who have received or plan to receive endovascular interventional treatment (including endovascular mechanical thrombectomy, intravascular thrombus aspiration, arterial thrombolysis, angioplasty and stenting) or patients with arteriovenous bridging therapy after this onset;\n* 3\\. Patients with disturbance of consciousness (NIHSS score Ia\\>1 point);\n* 4\\. Patient has a history of intracranial hemorrhage before;\n* 5\\. Patient who have a history of epilepsy or who experienced epileptic symptoms during a stroke;\n* 6\\. The patient with other mental illness (such as severe mental disorders, dementia) and combined conditions such as limb movement disorders may influence their neurological function tests;\n* 7\\. Patients with acute myocardial infarction, cardiac interventional therapy, or heart failure (grade III and IV according to NYHA) within the past 1 month;\n* 8\\. Patients with malignant tumors, serious diseases of blood, digestion or other systems or diseases with bleeding tendencies (such as hemophilia, etc.), and the expected survival time is not more than 3 months;\n* 9\\. Despite active antihypertensive therapy, hypertension remains uncontrolled: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg;\n* 10.Patients with severe liver function impairment, or ALT, AST \\> 2.0× ULN;\n* 11.Patients with severe renal impairment, or serum creatinine \\> 1.5× ULN;\n* 12.Patients who have used neuroprotective drugs (including Edaravone, Edaravone Dexborneol, Butylphthalide, Piracetam, Urinary Kallidinogenase, Ginkgolide, Ginkgo Diterpene Lactone, Safflower Extract and Aceglutamide Injection, etc.) after the onset of this illness;\n* 13.Patients with severe allergies, hypersensitivity to at least two or more types of drugs, or known to be allergic to any ingredient or excipient of the investigational drug;\n* 14.Patients with a history of major surgery within 1 month before screening;\n* 15.Patients with a history of drug abuse within 3 month before screening;\n* 16.Patients who participated in or are currently participating in other clinical trials within 3 month prior to this study;\n* 17.Pregnancy, lactation. or patients who have a family plan within 3 months of the first dose and who are unwilling to use contraception;\n* 18.The investigator considers that patients are not suitable for clinical trials.","80 Years",{"count":72,"type":20},300,[23],"This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.",[76],"Acute Ischemic Stroke","RECRUITING","2025-12-09",{"date":80,"type":31},"2025-12-12",{"date":82,"type":31},"2025-11-22",{"date":84,"type":20},"2026-10-18",{"name":36,"class":37},23,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":61},"100582753","phase-1-a-trial-to-evaluate-kpc000154-tablets-in-healthy-subjects-100582753","NCT06867406","A Trial to Evaluate KPC000154 Tablets in Healthy Subjects","A Phase I, Single-Center, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KPC000154 Tablets in Healthy Adult Volunteers","KPC000154","Inclusion Criteria:\n\n1. Subjects must fully understand the purpose, nature, procedures of the trial, and potential adverse reactions, and voluntarily participate as subjects, signing an informed consent form prior to the commencement of any study procedures.\n2. Healthy male and female subjects aged 18 to 55 years (inclusive of boundary values), with multiple-dose administration trials requiring subjects to have low-density lipoprotein cholesterol (LDL-C) levels that are either close to or at the borderline elevation (i.e., 2.8 mmol\u002FL (110 mg\u002FdL) ≤ LDL-C \\\u003C 4.1 mmol\u002FL (160 mg\u002FdL)) are eligible for inclusion.\n3. Male subjects must weigh ≥ 50.0 kg, and female subjects ≥ 45.0 kg; single-dose administration trials require a body mass index (BMI) within the range of 19.0-26.0 kg\u002Fm² (inclusive of boundary values), while multiple-dose administration trials require a BMI within the range of 19.0-30.0 kg\u002Fm² (inclusive of boundary values).\n4. Subjects must utilize effective contraceptive measures during the trial period and for six months after the last administration of the investigational drug, and must not plan to conceive, donate sperm, or donate ova.\n5. Subjects must be capable of effective communication with the investigators and understand and comply with all requirements of this study.\n\nExclusion Criteria:\n\n1. Individuals with an allergic constitution (e.g., known allergies to two or more medications or foods), or a history of allergies to KPC000154 or related excipients.\n2. Individuals with acute illnesses occurring within two weeks prior to screening.\n3. Individuals who have used any medication (including prescription drugs, over-the-counter drugs, traditional Chinese medicine preparations, and herbal remedies), health supplements, or functional vitamins within two weeks prior to screening.\n4. Individuals who have used inhibitors or inducers of CYP3A4, CYP2B6, CYP2C8, CYP2C9, or BCRP within one month prior to screening (e.g., inducers-rifampicin, phenobarbital, carbamazepine, phenytoin; inhibitors-itraconazole, voriconazole, tenofovir, ketoconazole, azithromycin, amiodarone, verapamil, sertraline, perphenazine, thioridazine, dapsone, montelukast, quercetin, phenformin, sulfamethoxazole, tinidazole, clarithromycin, ritonavir, gemfibrozil, clopidogrel, fluconazole, icatibant, aspergillus fumigatus toxin C, neomycin, sulfasalazine, curcumin, elvitegravir, cyclosporine A).\n5. Individuals with a history of chronic or severe diseases affecting the cardiovascular, liver, kidney, respiratory, hematopoietic, lymphatic, endocrine, immune, psychiatric, neurological, or gastrointestinal systems, or individuals with gastrointestinal, liver, kidney, or thyroid diseases that could affect drug absorption or metabolism within one year prior to screening.\n6. Individuals with a history of photosensitivity, or those currently undergoing antibiotic treatment for acne, or those with a history of or currently suffering from immunodeficiency diseases, lupus erythematosus, or immune dysfunction.\n7. Individuals with abnormal clinical significance in physical examination, vital signs, clinical laboratory tests (blood biochemistry tests with ALT \\> 1.5 times ULN, or AST \\> 1.5 times ULN, or total bilirubin \\> 1.5 times ULN), chest X-ray, cardiac ultrasound (only for multiple-dose trials), abdominal ultrasound (liver, gallbladder, spleen, pancreas, kidneys), and electrocardiogram, as assessed by the investigator (Note: In multiple-dose trials, blood biochemistry tests showing borderline elevations in total cholesterol and triglycerides do not constitute clinically significant abnormalities, i.e., total cholesterol \\\u003C 6.2 mmol\u002FL (240 mg\u002FdL), triglycerides \\\u003C 3.4 mmol\u002FL (300 mg\u002FdL)).\n8. Individuals who cannot abstain from consuming beverages and foods containing caffeine or alcohol (including chocolate, tea, coffee, cola, etc.), or grapefruit, grapefruit products, dragon fruit, mango, pomelo, orange, starfruit, guava, etc., which affect drug metabolism, or individuals who cannot stop smoking from 48 hours before dosing until the end of the trial.\n9. Individuals with prolonged QTc interval on ECG at screening: males with QTcF \\> 450 ms or females with QTcF \\> 470 ms (corrected by Fridericia's formula, calculated as QTcF = QT\u002F(RR\\^0.33)).\n10. Individuals with glomerular filtration rate (GFR) \\\u003C 90 mL\u002Fmin (calculated using the simplified MDRD formula: males: eGFR = 186 × creatinine (mg\u002FdL)\\^(-1.154) × age\\^(-0.203); females: eGFR = 186 × creatinine (mg\u002FdL)\\^(-1.154) × age\\^(-0.203) × 0.742); Note: creatinine units are mg\u002FdL, and creatinine results in μmol\u002FL must be converted to mg\u002FdL for calculation, 1 μmol\u002FL = 0.01131 mg\u002FdL.\n11. Individuals with any disease that increases the risk of gastrointestinal bleeding, such as acute gastritis or gastric and duodenal ulcers.\n12. Individuals who have undergone major surgical procedures within six months prior to screening (excluding diagnostic surgeries), or those planning to undergo surgery during the study, or those who have undergone surgeries judged by the investigator to affect drug absorption, distribution, metabolism, or excretion.\n13. Individuals who have received any vaccinations within four weeks prior to screening, or those planning to receive any vaccinations during the trial.\n14. Individuals who have participated in other clinical trials within three months prior to screening (Note: the end time is defined as the last date of participation in the clinical trial).\n15. Individuals who have engaged in blood donation within three months prior to screening, or those who have experienced blood loss (excluding menstrual blood loss) totaling 400 mL or more within six months prior to screening.\n16. Individuals with a history of alcohol consumption, i.e., an average weekly intake exceeding 2 units of alcohol (1 unit = 360 mL of beer or 45 mL of liquor with 40% alcohol content or 150 mL of wine) within one year prior to screening, or those who cannot abstain from alcohol during the trial, or those with alcohol breath test results \\> 0.0 mg\u002F100 mL.\n17. Individuals with an average daily smoking rate exceeding 5 cigarettes within three months prior to screening, or those with positive cotinine urine tests.\n18. Individuals with a history of drug abuse (including non-medical use of various anesthetics and\u002For psychotropic drugs) within one year prior to screening, or those with positive drug abuse screening (including morphine, methamphetamine, ketamine, ecstasy (MDMA), marijuana (THC), etc.).\n19. Individuals who cannot tolerate venipuncture\u002Findwelling catheters, or those with difficulties in blood collection, or those with a history of fainting at the sight of blood.\n20. Individuals with swallowing difficulties, or special dietary requirements, who cannot accept uniform diets.\n21. Individuals with hereditary fructose intolerance or glucose\u002Fgalactose absorption disorders, or those with sucrose-isomaltase deficiency.\n22. Individuals deemed by the investigator to have other conditions unsuitable for inclusion.\n23. Female subjects who have used oral contraceptives within 30 days prior to screening.\n24. Female subjects who have used long-acting estrogens or progestins (including progesterone-releasing intrauterine devices) or implant contraceptives within six months prior to screening.\n25. Female subjects who have engaged in unprotected sexual intercourse with partners within 14 days prior to screening.\n26. Female subjects with positive pregnancy tests or test results outside the normal range or not within the non-pregnant state range.\n27. Pregnant or lactating women.","55 Years",{"count":97,"type":20},92,[49],"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KPC000154 Tablets in Healthy Subjects",[101],"Healthy Subjects、Lipid Metabolism","2025-03-07",{"date":104,"type":31},"2025-03-10",{"date":102,"type":20},{"date":107,"type":20},"2026-01-31",{"name":36,"class":37},""]